Skip to main content
Equibles

D. E. Shaw & Co., Inc.

Position in FTRE — Fortrea Holdings Inc.

CIK 1009207 New York, NY
Back to FTRE Full portfolio

Position in FTRE

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$2,211,939
+$1,712,397 QoQ
Shares Held
127,123
+139.7% QoQ
Ownership
0.134%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#77
of 334 holders
Holding Since
Sep 2023
10 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in FTRE Over Time

Shares Held

Position Value (USD)

Derivatives in FTRE

reported options exposure · as of Dec 31, 2023
CallValue
$0
CallShares
0
PutValue
$383,900
PutShares
11,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

D. E. Shaw & Co., Inc. holds $5,139,216,221 across 217 Biotechnology names. FTRE ranks #129 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 5,877,959 $626,707,987
2 ALNY
Alnylam Pharmaceuticals, Inc.
 1,104,109 $332,369,932
3 EXEL
Exelixis, Inc.
 5,551,747 $302,070,554
4 BBIO
BridgeBio Pharma, Inc.
 3,633,007 $270,586,360
5 TGTX
Tg Therapeutics, Inc.
 3,400,808 $186,840,390
6 HALO
Halozyme Therapeutics, Inc.
 2,006,479 $157,047,110
7 AXSM
Axsome Therapeutics, Inc.
 604,753 $148,025,391
8 PTCT
Ptc Therapeutics, Inc.
 1,548,919 $126,345,322

All Filings in FTRE

Export CSV
12 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,211,939 127,123
2026-03-31 $499,542 53,030
2025-12-31 $10,431,523 604,726
2025-09-30 $9,083,293 1,078,776
2025-06-30 $5,212,939 1,055,251
2024-12-31 $225,665 12,100
2024-06-30 $308,088 13,200
2024-03-31 $3,791,182 94,449
2023-12-31 $383,900 11,000
2023-12-31 $2,003,538 57,408
2023-09-30 $314,490 11,000
2023-09-30 $463,015 16,195